HK1210173A1 - Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators - Google Patents

Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators Download PDF

Info

Publication number
HK1210173A1
HK1210173A1 HK15111080.1A HK15111080A HK1210173A1 HK 1210173 A1 HK1210173 A1 HK 1210173A1 HK 15111080 A HK15111080 A HK 15111080A HK 1210173 A1 HK1210173 A1 HK 1210173A1
Authority
HK
Hong Kong
Prior art keywords
nicotinamides
amino
substituted
bearing
containing group
Prior art date
Application number
HK15111080.1A
Other languages
English (en)
Chinese (zh)
Inventor
Simon Lucas
Sven KÜHNERT
Gregor Bahrenberg
Wolfgang Schröder
Achim Kless
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of HK1210173A1 publication Critical patent/HK1210173A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
HK15111080.1A 2012-04-18 2013-04-17 Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators HK1210173A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12002709 2012-04-18
EP12002709.9 2012-04-18
PCT/EP2013/001134 WO2013156154A1 (en) 2012-04-18 2013-04-17 Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators

Publications (1)

Publication Number Publication Date
HK1210173A1 true HK1210173A1 (en) 2016-04-15

Family

ID=48227140

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111080.1A HK1210173A1 (en) 2012-04-18 2013-04-17 Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators

Country Status (21)

Country Link
EP (1) EP2888233B1 (cg-RX-API-DMAC10.html)
JP (1) JP6033403B2 (cg-RX-API-DMAC10.html)
CN (1) CN104428287A (cg-RX-API-DMAC10.html)
AR (1) AR090739A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013248637A1 (cg-RX-API-DMAC10.html)
BR (1) BR112014025840A2 (cg-RX-API-DMAC10.html)
CA (1) CA2870573A1 (cg-RX-API-DMAC10.html)
CY (1) CY1118255T1 (cg-RX-API-DMAC10.html)
DK (1) DK2888233T3 (cg-RX-API-DMAC10.html)
EA (1) EA201401142A1 (cg-RX-API-DMAC10.html)
ES (1) ES2605947T3 (cg-RX-API-DMAC10.html)
HK (1) HK1210173A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20161424T1 (cg-RX-API-DMAC10.html)
HU (1) HUE030859T2 (cg-RX-API-DMAC10.html)
IL (1) IL235030A0 (cg-RX-API-DMAC10.html)
LT (1) LT2888233T (cg-RX-API-DMAC10.html)
MX (1) MX2014012494A (cg-RX-API-DMAC10.html)
PT (1) PT2888233T (cg-RX-API-DMAC10.html)
RS (1) RS55466B1 (cg-RX-API-DMAC10.html)
SI (1) SI2888233T1 (cg-RX-API-DMAC10.html)
WO (1) WO2013156154A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3447047A1 (en) * 2016-04-22 2019-02-27 ONO Pharmaceutical Co., Ltd. Crystal polymorphism of kcnq 2-5 channel activator
WO2019130185A1 (en) * 2017-12-29 2019-07-04 3M Innovative Properties Company Thermally curable two part processing adhesive composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2230392A1 (de) 1972-06-22 1974-01-31 Cassella Farbwerke Mainkur Ag Substituierte pyridinverbindungen und verfahren zu ihrer herstellung
DE2513949A1 (de) 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
CZ20032233A3 (cs) 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
MXPA03007397A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
EP2086935A1 (de) * 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
JP2012506395A (ja) 2008-10-24 2012-03-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 痛み、てんかん、及び尿失禁の治療のためのｋｃｎｑ２／３モジュレーターとしての置換された４，５，６，７−テトラヒドロチエノピリジン
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
CA2815131C (en) * 2010-10-20 2020-06-09 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as kcnq2/3 modulators

Also Published As

Publication number Publication date
WO2013156154A1 (en) 2013-10-24
EP2888233B1 (en) 2016-09-28
AR090739A1 (es) 2014-12-03
CN104428287A (zh) 2015-03-18
AU2013248637A1 (en) 2014-12-04
BR112014025840A2 (pt) 2017-07-18
CA2870573A1 (en) 2013-10-24
JP2015514728A (ja) 2015-05-21
JP6033403B2 (ja) 2016-11-30
EA201401142A1 (ru) 2015-03-31
CY1118255T1 (el) 2017-06-28
HRP20161424T1 (hr) 2016-12-16
DK2888233T3 (en) 2017-01-09
SI2888233T1 (sl) 2016-12-30
HUE030859T2 (en) 2017-06-28
EP2888233A1 (en) 2015-07-01
PT2888233T (pt) 2017-01-04
MX2014012494A (es) 2015-01-15
ES2605947T3 (es) 2017-03-17
RS55466B1 (sr) 2017-04-28
LT2888233T (lt) 2017-01-10
IL235030A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2013163190A8 (en) Dna-pk inhibitors
WO2015001504A3 (en) Antibody formulations and methods
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
HK1213264A1 (zh) 经取代的苯化合物
PH12013502240B1 (en) Novel compounds as modulators of protein kinase
WO2014062720A3 (en) Methods of treating cancer
WO2013013815A8 (en) Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands
HK1206028A1 (en) Phenicol antibacterials
EP4414376A3 (en) Novel depsipeptide and uses thereof
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
MX2013011421A (es) Derivados de pirazolo-pirimidina.
HK1258456A1 (zh) 吡唑基取代的四氢吡喃碸
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2014082738A8 (en) Heteroquinoline-3-carboxamides as kcnq2/3 modulators
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
MX2013002119A (es) Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3.
HK1258461A1 (zh) 吡唑基取代的四氢吡喃碸